Anti-tau antibody reduces insoluble tau and decreases brain atrophy.
Wiley Online Library; DOI: 10.1002/acn3.176.
Human secreted tau increases amyloid-beta production.
ScienceDirect; doi:10.1016/j.neurobiolaging.2014.09.007.
Sustained high levels of neuroprotective, high molecular weight, phosphorylated tau in the longest-lived rodent.
ScienceDirect; doi:10.1016/j.neurobiolaging.2014.12.004.
Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models.
PLOS One; DOI: 10.1371/journal.pone.0125614.
C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
The Journal of the Alzheimer’s Association; doi.org/10.1016/j.jalz.2015.05.012.
Effects of antibodies to phosphorylated and non-phosphorylated tau on in vitro tau phosphorylation at Serine-199: Preliminary report.
ScienceDirect; doi:10.1016/j.exger.2015.04.010.
Brain-derived neurotrophic factor and TrkB expression in the “oldest-old,” the 90+ Study: correlation with cognitive status and levels of soluble amyloid-beta.
ScienceDirect; doi:10.1016/j.neurobiolaging.2015.08.022.
A novel tau mutation, p.K317N, causes globular glial tauopathy.
Springer Link; doi:10.1007/s00401-015-1425-0.
QUANTIFICATION OF TAU IN BIOLOGICAL SAMPLES BY IMMUNOAFFINITY ENRICHMENT AND MASS SPECTROMETRY.
Free Patents Online; http://www.freepatentsonline.com/y2015/0253341.html.
HUMAN ANTI-TAU ANTIBODIES.
Free Patents Online; http://www.freepatentsonline.com/y2015/0252102.html.